Literature DB >> 6278093

Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas.

A Arregui, E K Perry, M Rossor, B E Tomlinson.   

Abstract

The activity of the dipeptidyl carboxypeptidase, angiotensin converting enzyme, was assayed in several brain regions of patients dying with Alzheimer's disease and compared to that of appropriately age-matched controls. Enzyme activity was found to be elevated by 44% and 41% in the medial hippocampus and parahippocampal gyrus, respectively, and by 27% and 29% in the frontal cortex (area 10 of Brodman) and caudate nucleus, respectively, in Alzheimer's disease patients. Converting enzyme activity did not differ from controls in the nucleus accumbens, substantia nigra, temporal cortex, anterior or posterior hippocampus, amydgala, and septal nuclei.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6278093     DOI: 10.1111/j.1471-4159.1982.tb07930.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  30 in total

1.  The angiotensin-converting enzyme gene as a possible risk or protective factor in Alzheimer's disease.

Authors:  T V Shcherbatykh; S A Kiryanov; G I Korovaitseva; N D Selezneva; N I Voskresenskaya; V E Golimbet; L Farrer; S I Gavrilova; E I Rogaev
Journal:  Neurosci Behav Physiol       Date:  2001 Mar-Apr

2.  No association of angiotensin I converting enzyme I/D polymorphism with domain-specific cognitive function in aged men without dementia.

Authors:  Mu-En Liu; Shih-Jen Tsai; Ti Lu; Cheng-Jee Hong; Ming-Chao Chen; Shoa-Lin Lin; Heng-Liang Yeh; Yan-Chiou Ku
Journal:  Neuromolecular Med       Date:  2011-08-11       Impact factor: 3.843

3.  Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor.

Authors:  Matthew L Hemming; Dennis J Selkoe
Journal:  J Biol Chem       Date:  2005-09-09       Impact factor: 5.157

4.  Angiotensin I converting enzyme polymorphism effects in patients with normal pressure hydrocephalus syndrome before and after surgery.

Authors:  Maria del Mar Matarín; Maria Antonia Poca; David Bartrés-Faz; Maria Mataró; Imma C Clemente; Cristina Solé-Padullés; Emili González-Pérez; Pedro Moral; Maite Barrios; Carme Junqué; Juan Sahuquillo
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

5.  Somatostatin Receptor Subtype-4 Regulates mRNA Expression of Amyloid-Beta Degrading Enzymes and Microglia Mediators of Phagocytosis in Brains of 3xTg-AD Mice.

Authors:  Karin Sandoval; David Umbaugh; Austin House; Albert Crider; Ken Witt
Journal:  Neurochem Res       Date:  2019-10-19       Impact factor: 3.996

6.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

Authors:  Scott Miners; Emma Ashby; Shabnam Baig; Rachel Harrison; Hannah Tayler; Elizabeth Speedy; Jonathan A Prince; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2009-01-18       Impact factor: 4.060

Review 7.  Proteases of human brain.

Authors:  A Pope; R A Nixon
Journal:  Neurochem Res       Date:  1984-03       Impact factor: 3.996

Review 8.  Hypertension and dementia.

Authors:  Olivier Hanon; Marie Laure Seux; Hermine Lenoir; Anne Sophie Rigaud; Françoise Forette
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 9.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 10.  The Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer's Disease.

Authors:  Chao-Liang Chou; Hung-I Yeh
Journal:  Acta Cardiol Sin       Date:  2014-03       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.